Journal of Experimental Medicine is now presenting opportunities to engage in Continuing Medical Education (CME) in collaboration with Memorial Sloan Kettering Cancer Center. Each Journal-Based CME activity consists of a full-text article that is free to read, a multiple-choice question test, and an evaluation/self-assessment.
Researchers in Japan have developed a vaccination strategy in mice that promotes the production of antibodies that can neutralize not only SARS-CoV-2 but a broad range of other coronaviruses as well. If successfully translated to humans, the approach, to be published October 8 in the Journal of Experimental Medicine, could lead to the development of a next-generation vaccine capable of preventing future coronavirus pandemics.
Virginia’s academic library consortium, VIVA, and Rockefeller University Press (RUP) have entered into a Read-and-Publish Agreement. This agreement is the first of its kind for RUP in the United States and represents an important milestone in its transition to being fully Open Access. It offers a sustainable framework and provides unlimited access to all content and unlimited immediate open access publishing.
Rockefeller University Press (RUP) has attained Plan S compliant Transformative Journal status from cOAlition S. Authors receiving funding from members of cOAlition S may be eligible to have their Immediate Open Access (OA) fees covered in Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM), and Journal of General Physiology (JGP).
To address equity in Open Access publishing and promote important global research, publication fees for Immediate Open Access under CC-BY license in Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM), and Journal of General Physiology (JGP) are automatically waived for corresponding authors based in eligible developing countries. This includes deposit in PubMed Central (PMC) and archive in LOCKSS/CLOCKSS and Portico.
A team of researchers from the University of California, San Francisco (UCSF), Stanford University, and the California Academy of Sciences (CAS) has uncovered new clues as to how poisonous frogs and birds avoid intoxicating themselves.
Researchers in Singapore have discovered that brain cells cannot maintain the cholesterol-rich myelin sheath that protects and insulates neurons in the absence of a protein called TDP-43. The study, which will be published August 4 in the Journal of Cell Biology (JCB), suggests that restoring cholesterol levels could be a new therapeutic approach for diseases associated with TDP-43, such as amyotrophic lateral sclerosis and frontotemporal dementia.
Researchers at Weill Cornell Medicine and NewYork-Presbyterian in New York have discovered that injecting mice with pulmonary endothelial cells—the cells that line the walls of blood vessels in the lung—can reverse the symptoms of emphysema. The study, which will be published July 21 in the Journal of Experimental Medicine (JEM), may lead to new treatments for chronic obstructive pulmonary disease (COPD), an inflammatory lung disease associated with smoking that is thought to be the third leading cause of death worldwide.
Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM), and Journal of General Physiology (JGP) announce an editorial policy allowing swift and confidential updates to author names at any time and for any reason including changes to gender identity, marriage, divorce, religion, or other personal circumstances.
Researchers in Italy have identified a pair of microRNA molecules that help maintain a population of cancerous stem cells that drive the growth of breast cancers and initiate tumor relapse after treatment. The study, which will be published April 2 in the Journal of Cell Biology (JCB), reveals that targeting these microRNAs makes cancer stem cells more susceptible to some chemotherapies and could potentially improve the prognosis of patients with aggressive forms of breast cancer.
Researchers at the University of California, San Francisco, have discovered that aggressive, triple-negative breast cancers (TNBCs) can evade treatment by reorganizing and softening the collagen matrix that surrounds the cancer cells. The study, which will be published April 2 in the Journal of Experimental Medicine (JEM), shows that the softer matrix activates a signaling pathway that promotes the cancer cells’ survival, and suggests that targeting this pathway could enhance the effectiveness of chemo- and radiotherapy in TNBC patients.
Researchers at the University of Alabama at Birmingham have identified a new molecular target that could potentially treat the deadly, aging-related lung disease idiopathic pulmonary fibrosis (IPF). The study, which will be published March 10 in the Journal of Experimental Medicine (JEM), suggests that targeting a protein called MDM4 could prevent respiratory failure by initiating a genetic program that removes scar tissue from the lungs.
Researchers at the University of California San Diego School of Medicine and Massachusetts General Hospital have identified a new drug that could prevent Alzheimer’s disease by modulating, rather than inhibiting, a key enzyme involved in forming amyloid plaques in the brain. The study, which will be published March 2 in the Journal of Experimental Medicine (JEM), demonstrates that the drug is safe and effective in rodents and monkeys, paving the way for future clinical trials in humans.
By analyzing blood samples from individuals infected with SARS-CoV-2, researchers in Singapore have begun to unpack the different responses by the body’s T cells that determine whether or not an individual develops COVID-19. The study, published today in the Journal of Experimental Medicine (JEM), suggests that clearing the virus without developing symptoms requires T cells to mount an efficient immune response that produces a careful balance of pro- and anti-inflammatory molecules.
Researchers at McGill University have identified a new cellular pathway that limits the growth and spread of brain tumors by controlling the recycling of cell surface receptor proteins. The study, which will be published January 14 in the Journal of Cell Biology (JCB), suggests that the pathway, which involves a protein called Rab35, is defective in many patients with glioblastoma and that restoring Rab35’s activity could be a new therapeutic strategy for this deadly form of brain cancer.
Max Planck Digital Library (MPDL) has signed an unlimited “read-and-publish” transformative agreement with Rockefeller University Press (RUP) on behalf of the Max Planck Society. The agreement covers Open Access (OA) publishing of articles in RUP’s three hybrid journals: Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM) and Journal of General Physiology (JGP).
Using both mouse and human brain tissue, researchers at Yale School of Medicine have discovered that SARS-CoV-2 can directly infect the central nervous system and have begun to unravel some of the virus’s effects on brain cells. The study, published today in the Journal of Experimental Medicine (JEM), may help researchers develop treatments for the various neurological symptoms associated with COVID-19.
Activating an immune signaling pathway best known for fighting viral and bacterial infections can boost the ability of genetically engineered T cells to eradicate breast cancer in mice, according to a new study by researchers at the University of North Carolina. The study, to be published December 31 in the Journal of Experimental Medicine (JEM), suggests that CAR T cells, which are already used to treat certain blood cancers in humans, may also be successful against solid tumors if combined with other immunotherapeutic approaches.
Researchers at the University of Utah School of Medicine have identified a new therapeutic target to treat patients with type 1 diabetes. The study, which will be published December 9 in the Journal of Experimental Medicine (JEM), reveals that inhibiting a protein called OCA-B protects mice from type 1 diabetes by limiting the activity of immune cells that would otherwise destroy the pancreas’ insulin-producing β cells.
Pairs of antibodies may be more effective than single antibodies at preventing and treating COVID-19, according to a new study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University in New York. The study, published November 19 in the Journal of Experimental Medicine (JEM), also suggests that in addition to blocking SARS-CoV-2’s entry into cells, the antibodies may combat the virus by enlisting various types of white blood cells to fight the infection.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right